Targacept Announces Initiation of Phase 2b Study of TC-5214 in Overactive Bladder

barbara.lempert

Winston-Salem, NC—May 29, 2013—, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics ™, today announced the of a 2b clinical of TC-5214 as a treatment for (OAB).  TC-5214 acts potently on alpha3beta4 and other neuronal nicotinic receptors (NNRs) located in or around the that are believed to play a key role in contraction and signaling of the urge to urinate.  Because orally administered TC-5214 is eliminated more than 90% unchanged through the , Targacept believes the compound offers potential for a low dose to be beneficial while minimizing systemic side effects characteristic of current therapies and enhancing patient compliance.
 
“Overactive bladder has a devastating effect on quality of life for millions of individuals, and currently available medications have significant drawbacks,” said Eric Rovner, M.D., Professor of Urology, Medical University of South Carolina, College of Medicine, and an investigator in Targacept’s study. “Based on the novel mechanism and favorable tolerability profile associated with TC-5214, I am encouraged by the potential for this clinical study to support what could be a truly novel therapy for patients who suffer from OAB.”
 
TC-5214 was associated with exaggerated bladder effects in preclinical studies, including increased urinary retention and beneficial changes in bladder contraction, bladder capacity and frequency of urination.  In addition, TC-5214 already has a substantial safety database resulting from prior clinical studies in approximately 2,400 subjects in a different indication.
 
“With a strong scientific rationale, supportive findings, measurable clinical endpoints and a well-defined regulatory path, we view overactive bladder as a promising indication for development of this advanced compound,” said Dr. Stephen A. Hill, Targacept’s President and Chief…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS